They feel that our national drug review agency – the Common Drug Review (CDR) – is applying an inappropriate, inadequate and unethical health economic assessment to orphan drugs, resulting in the denial of nearly every orphan drug presented to the CDR.
The Standing Committee on Health is evaluating the CDR and will hear testimony on April 25th from the Federal, Provincial and Territorial governments that fund and operate the CDR. “We felt it was essential that Committee members have in mind the concerns of the patients as they listen to the government managers of CDR,” says Wong-Rieger.
Newsmaker breakfast: The CDR and rare Diseases
Hosted by Durhane Wong-Rieger, President of CORD
Ms. Wong-Rieger will discuss the shortcomings of CDR assessment of drugs for rare disorders and the need for an alternative solution. The issues will be exemplified by Tony Clark, a patient diagnosed with Renal Cell Carcinoma – a rare and terminal disorder – who will share his story.
April 24, 2007
7:30 – 8:00am – media registration
8:00am – breakfast is served
8:15 – 8:45am – keynote address
8:45am – Q&A and interview opportunities
The National Press Club of Canada
150 Wellington, Ottawa, ON KIP 5A4
South Entrance: 165 rue Sparks Street
Durhane Wong-Rieger, President of CORD
Tony Clark, Kidney cancer patient
Deborah Maskens, cancer patient
One-on-one interviews with participants
B-roll will be made available
Please confirm attendance with the National Press Club at 613-233-5641 or with Steven Lott (contact information below).
For further information: Steven Lott, Communications Director, Ward Health Strategies, (905) 577-6200 ext. 424, (905) 928-5688 (cell), [email protected]
Copyright 2005 Groupe CNW LtÃ©e